Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Cardiovascular by Phase

  • There are currently 4597 ongoing clinical trials involving Cardiovascular

  • Of the 4597 trials,1589 trials are in Phase II

  • Furthermore, 7290 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Cardiovascular by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Cardiovascular therapy area. The largest number of ongoing clinical trials for indications related to cardiovascular therapy area is conducted in the Asia-Pacific region. Europeand North Americaare among some of the other prominent regions involved in drug trials.

Yonsei University: The leading ongoing clinical trial sponsor for indications related to cardiovascular therapy area

Yonsei Universityis the top clinical trial sponsor for indications related to the cardiovascular therapy area.

Assistance Publique - Hopitaux de Paris, Vanderbilt University Medical Center, and Beijing Anzhen Hospital are a few other notable clinical trials sponsors involved in Cardiovascular therapy area. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cardiovascular

Adalimumab (Humira), Apixaban (Eliquis), and Rivaroxaban (Xarelto) are among the key marketed drugs marketed for the treatment of indications related to the cardiovascular therapy area.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as an injection for subcutaneous route of administration. Adalimumab is marketed for the treatment of several indications including Pyoderma Gangrenosum, Axial Spondyloarthritis, Hidradenitis Suppurativa, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Anterior Uveitis, Behcet Disease, Intermediate Uveitis, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Posterior Uveitis. It was first approved in 2002 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including AbbVieIncEisaiCoLtd, and Abbott Laboratories.

Apixaban (Eliquis) is a phenylpiperidine derivative, acts as antithrombotic or anticoagulant agent. It functions via Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC Inhibitor mechanism of action. Apixaban is formulated as tablets and film-coated tablets for oral route of administration. Eliquis ismarketed for the treatment of several indications including Venous Thromboembolism, Stroke, Ischemic Stroke, Pulmonary Embolism, Hemorrhage, Deep Vein Thrombosis (DVT), Thromboembolism, and Venous (Vein) Thrombosis. Apixaban was first approved in 2011and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Pfizer Inc, and Bristol-Myers Squibb Co.

Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.


Access more premium companies when you subscribe to Explorer